---
title: "Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Real-world evidence questions"
description: "Real-world evidence questions on Paxlovid (nirmatrelvir; ritonavir) in COVID-19, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What did a real-world study (Lewnard) show for Paxlovid and hospitalization? Does Paxlovid work in vaccinated patients in a real-world study (Lewnard)? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/paxlovid--covid-19/real-world-evidence"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Real-world evidence questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)

Questions that apply to every indication of Paxlovid are on [Paxlovid (nirmatrelvir; ritonavir), all indications](https://www.evicenter.com/medical-information/paxlovid).

## Real-world evidence

<a id="paxlovid-rwe-lewnard"></a>

### What did a real-world study (Lewnard) show for Paxlovid and hospitalization?

> “Objective
> To estimate the effectiveness of PAXLOVID in preventing severe outcomes of SARS-CoV-2 infection by retrospective analysis of real-world patients in an outpatient setting within a large, integrated US healthcare system.
>
> Primary endpoint
> Hospital admission or death from any cause within 30 days of a positive SARS-CoV-2 test in the subgroup that took PAXLOVID within 5 days of symptom onset.
>
> Study design
> Analysis was carried out within Kaiser Permanente Southern California (KPSC), a large, integrated US healthcare database
> Data from patients who received a positive SARS-CoV-2 PCR test result between April 8, 2022, and October 7, 2022, were analyzed
> The clinical outcomes associated with PAXLOVID treatment were analyzed by matching treated and untreated patients
> Adjusted hazard ratios were calculated via the Cox proportional hazards model and used to determine the estimated effectiveness of PAXLOVID”

Source: [PAXLOVID: Lewnard Study, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/real-world-evidence-study#:~:text=Objective,the%20estimated%20effectiveness%20of%20PAXLOVID)

> “79.6% estimated effectiveness against hospital admission or death
> Patients treated within 5 days of symptom onset
> 95% CI, 33.9-93.8, P=0.0080
> The effectiveness of PAXLOVID in preventing the primary endpoint was calculated as (1-aHR) x 100%, estimating the aHR via Cox proportional hazards models and comparing the outcomes among patients who received or did not receive PAXLOVID”

Source: [PAXLOVID: Lewnard Study, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/real-world-evidence-study#:~:text=79.6%25%20estimated%20effectiveness%20against%20hospital,or%20did%20not%20receive%20PAXLOVID)

> “Were ≥12 years old at the time of their index test”

Source: [PAXLOVID: Lewnard Study, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/real-world-evidence-study#:~:text=Were%20%E2%89%A512%20years%20old%20at%20the%20time%20of%20their%20index%20test)

> “RWE analyses can only evaluate association and not causation, and therefore are answering different questions from RCTs”

Source: [PAXLOVID: Real-World Evidence, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/real-world-evidence#:~:text=RWE%20analyses%20can%20only%20evaluate,answering%20different%20questions%20from%20RCTs)

Note: This retrospective cohort study (Lewnard JA, et al. Lancet Infect Dis. 2023) is presented on the Paxlovid HCP site. Its inclusion criteria admitted patients 12 years and older; Paxlovid is approved for adults. The inclusion criteria listed on the page do not require a risk factor for severe COVID-19. The page lists further study limitations, including incomplete capture of variables and possible unmeasured confounding.

<a id="paxlovid-rwe-lewnard-vaccinated"></a>

### Does Paxlovid work in vaccinated patients in a real-world study (Lewnard)?

> “In a subgroup analysis of vaccinated patients treated with PAXLOVID within 5 days of symptom onset, patients who had received ≥2 and ≥3 COVID-19 vaccine doses, the effectiveness of PAXLOVID against the primary endpoint when dispensed within 5 days of symptom onset was 83.1% and 92.2%, respectively (95% Cl, 30.4-95.9; 52.0-98.7)”

Source: [PAXLOVID: Lewnard Study, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/real-world-evidence-study#:~:text=In%20a%20subgroup%20analysis%20of,respectively%20%2895%25%20Cl%2C%2030.4%2D95.9%3B%2052.0%2D98.7%29)

> “Because of the low risk of severe disease within the highly vaccinated study population, the primary and secondary endpoints occurred rarely among both treatment recipients and nonrecipients, further limiting the precision of the estimates and the ability to explore effect modification.”

Source: [PAXLOVID: Lewnard Study, captured 2026-11-13](https://paxlovid.pfizerpro.com/efficacy-design/real-world-evidence-study#:~:text=Because%20of%20the%20low%20risk,ability%20to%20explore%20effect%20modification.)

Note: The study (Lewnard JA, et al. Lancet Infect Dis. 2023) analyzed Kaiser Permanente Southern California patients with a positive SARS-CoV-2 test between April 8 and October 7, 2022. The primary endpoint was hospital admission or death from any cause within 30 days. Its inclusion criteria admitted patients 12 years and older and did not require a risk factor for severe COVID-19; Paxlovid is approved for adults at high risk.

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)
- [Indication](https://www.evicenter.com/medical-information/paxlovid--covid-19/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/paxlovid--covid-19/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/paxlovid--covid-19/safety)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid--covid-19/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid--covid-19/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid--covid-19/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid--covid-19/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/paxlovid--covid-19/guidelines)
